Worth Watching Stock: Novavax, Inc. (NASDAQ:NVAX)

0
2145
touch screen graph on tablet

Novavax, Inc. (NASDAQ:NVAX) reported its last earnings on Aug 09 AMC (BMO = before market open, AMC= after market close). The company will report its next earnings on Nov 7 – Nov 11 (Est.). The company reported the earnings of $-0.29/Share in the last quarter where the estimated EPS by analysts was $-0.25/share. The difference between the expected and actual EPS was $-0.04/share, which represents an Earnings surprise of -16%.

Many analysts are providing their Estimated Earnings analysis for Novavax, Inc. and for the current quarter 8 analysts have projected that the stock could give an Average Earnings estimate of $-0.26/share. These analysts have also projected a Low Estimate of $-0.29/share and a High Estimate of $-0.23/share.

In case of Revenue Estimates, 6 analysts have provided their consensus Average Revenue Estimates for Novavax, Inc. as 4.12 Million. According to these analysts, the Low Revenue Estimate for Novavax, Inc. is 2 Million and the High Revenue Estimate is 5 Million. The company had Year Ago Sales of 6.52 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for NVAX to be -116.7%. They are projecting Next Quarter growth of 13.8%. For the next 5 years, Novavax, Inc. is expecting Growth of 0% per annum, whereas in the past 5 years the growth was 0% per annum.

Some buy side analysts are also providing their Analysis on Novavax, Inc., where 5 analysts have rated the stock as Strong buy, 3 analysts have given a Buy signal, 1 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 7 Analysts reported that the Price Target for Novavax, Inc. might touch $17 high while the Average Price Target and Low price Target is $8.74 and $1 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. Novavax, Inc. got Downgrade on 16-Sep-16 where investment firm Citigroup Downgrade the stock from Buy to Neutral.

Novavax, Inc. closed its last trading session at $2.2 with the loss of -6.36%. The Market Capitalization of the company stands at 558.65 Million. The Company has 52-week high of $9.23 and 52-week low of $1.16. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -58.98% where SMA50 and SMA200 are -67.7% and -66.01% respectively. The Company Touched its 52-Week High on Dec 2, 2015 and 52-Week Low on Sep 16, 2016.

The Relative Volume of the company is 1.82 and Average Volume (3 months) is 15.87 million. Novavax, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -56.3%. The Return on Equity (ROE) value stands at -112.4%. While it’s Return on Investment (ROI) value is -53.6%.

While looking at the Stock’s Performance, Novavax, Inc. currently shows a Weekly Performance of -4.19%, where Monthly Performance is -70.4%, Quarterly performance is -71.66%, 6 Months performance is -62.48% and yearly performance percentage is -70.86%. Year to Date performance value (YTD perf) value is -75.45%. The Stock currently has a Weekly Volatility of 11.00% and Monthly Volatility of 10.22%.